InvivoGen
InvivoGen was founded in 1997 by scientists with technical expertise and creative excellence stemming from a longstanding history in microbiology. InvivoGen's unparalleled skill in microbial fermentation enables them to provide a wide range of biological molecules, including ultra-pure antibiotics, novel mycoplasma treatments and the largest collection of pattern recognition receptor agonists derived from a wide range of micro-organisms.
More information at https://www.invivogen.com.
InvivoGen
Non-fucosylated human IgG1 monoclonal antibody against β-galactosidase; Isotype control
InvivoGen
Bispecific antibody against β-galactosidase and human CD3; Negative control
InvivoGen
Bispecific antibody against human CD19 and β-galactosidase; Negative control
